Resumen de acción TORNTPHARM
Torrent Pharmaceuticals Limited se dedica a la investigación, desarrollo, fabricación y comercialización de formulaciones farmacéuticas genéricas en India, Estados Unidos, Brasil, Alemania y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Competidores de Torrent Pharmaceuticals Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,691.00 |
| 52 Week High | ₹2,744.00 |
| 52 Week Low | ₹1,598.45 |
| Beta | 0.29 |
| 1 Month Change | 3.48% |
| 3 Month Change | 10.38% |
| 1 Year Change | 62.86% |
| 3 Year Change | 114.49% |
| 5 Year Change | 207.52% |
| Change since IPO | 22,325.00% |
Noticias y actualizaciones recientes
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Recent updates
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More
Mar 02Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?
Feb 10Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?
Jan 19Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?
Dec 29Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Dec 08
Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%
Nov 16The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 28Here's Why We Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Well Worth Watching
Oct 07Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Delivered A Better ROE Than Its Industry
Sep 16Rentabilidad de los accionistas
| TORNTPHARM | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | 6.0% | 2.3% | 2.6% |
| 1Y | 62.9% | 56.7% | 45.0% |
Rentabilidad vs. Industria: TORNTPHARM superó al sector Indian Pharmaceuticals , que obtuvo un rendimiento del 53.7% el año pasado.
Rentabilidad vs. Mercado: TORNTPHARM superó al mercado Indian, que obtuvo un rendimiento del 45% el año pasado.
Volatilidad de los precios
| TORNTPHARM volatility | |
|---|---|
| TORNTPHARM Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: TORNTPHARM no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TORNTPHARM (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1959 | 13,247 | Samir Mehta | www.torrentpharma.com |
Torrent Pharmaceuticals Limited se dedica a la investigación, desarrollo, fabricación y comercialización de formulaciones farmacéuticas genéricas en India, Estados Unidos, Brasil, Alemania y a escala internacional. La empresa ofrece productos en diversas áreas terapéuticas, como cardiovascular, sistema nervioso central, gastrointestinal y salud de la mujer; y diabetología, tratamiento del dolor, ginecología, oncología y antiinfecciosos, así como vitaminas, minerales y nutrientes. También ofrece servicios de fabricación por contrato.
Resumen de fundamentos de Torrent Pharmaceuticals Limited
| Estadísticas fundamentales de TORNTPHARM | |
|---|---|
| Capitalización bursátil | ₹910.57b |
| Beneficios(TTM) | ₹14.94b |
| Ingresos (TTM) | ₹104.74b |
60.9x
Ratio precio-beneficio (PE)8.7x
Ratio precio-ventas (PS)¿Está TORNTPHARM sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TORNTPHARM | |
|---|---|
| Ingresos | ₹104.74b |
| Coste de los ingresos | ₹27.11b |
| Beneficio bruto | ₹77.63b |
| Otros gastos | ₹62.69b |
| Beneficios | ₹14.94b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 44.15 |
| Margen bruto | 74.12% |
| Margen de beneficio neto | 14.27% |
| Ratio deuda/patrimonio | 66.9% |
¿Cómo se ha desempeñado TORNTPHARM a largo plazo?
Ver rendimiento histórico y comparativa